Brokerages Expect Ultragenyx Pharmaceutical Inc (RARE) Will Announce Quarterly Sales of $18.60 Million

Brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will announce sales of $18.60 million for the current quarter, Zacks reports. Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the highest sales estimate coming in at $22.10 million and the lowest estimate coming in at $16.10 million. Ultragenyx Pharmaceutical posted sales of $10.68 million in the same quarter last year, which would indicate a positive year over year growth rate of 74.2%. The business is expected to report its next quarterly earnings results on Monday, May 6th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $98.45 million for the current fiscal year, with estimates ranging from $69.27 million to $127.21 million. For the next fiscal year, analysts forecast that the firm will report sales of $206.21 million, with estimates ranging from $142.30 million to $257.54 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.01. The firm had revenue of $16.26 million for the quarter, compared to the consensus estimate of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%.

A number of equities analysts have recently weighed in on the company. Raymond James reiterated an “outperform” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 22nd. BidaskClub downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 20th. ValuEngine upgraded Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $88.00 target price on shares of Ultragenyx Pharmaceutical in a report on Monday, January 7th. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Ultragenyx Pharmaceutical presently has an average rating of “Buy” and an average target price of $76.84.

Shares of RARE opened at $69.36 on Monday. The stock has a market capitalization of $3.56 billion, a PE ratio of -9.39 and a beta of 2.21. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98.

In related news, CFO Shalini Sharp sold 14,800 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $70.00, for a total value of $1,036,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in RARE. Bank of New York Mellon Corp boosted its position in Ultragenyx Pharmaceutical by 1.9% during the second quarter. Bank of New York Mellon Corp now owns 207,662 shares of the biopharmaceutical company’s stock worth $15,963,000 after purchasing an additional 3,903 shares during the period. Wells Fargo & Company MN boosted its position in Ultragenyx Pharmaceutical by 5.3% during the third quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock worth $1,812,000 after purchasing an additional 1,194 shares during the period. Janney Montgomery Scott LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth approximately $313,000. Shell Asset Management Co. bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth approximately $435,000. Finally, Dimensional Fund Advisors LP boosted its position in Ultragenyx Pharmaceutical by 711.4% during the third quarter. Dimensional Fund Advisors LP now owns 61,947 shares of the biopharmaceutical company’s stock worth $4,729,000 after purchasing an additional 54,312 shares during the period. 98.59% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.